Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $52160.0.

  • Seres Therapeutics' Gains from Sales and Divestitures fell 9629.44% to $52160.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $52160.0, marking a year-over-year decrease of 9629.44%. This contributed to the annual value of $2.2 million for FY2024, which is 4400.56% up from last year.
  • Seres Therapeutics' Gains from Sales and Divestitures amounted to $52160.0 in Q3 2025, which was down 9629.44% from $35161.0 recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Gains from Sales and Divestitures peaked at $2.2 million during Q4 2024, and registered a low of $650.0 during Q1 2021.
  • For the 5-year period, Seres Therapeutics' Gains from Sales and Divestitures averaged around $442566.6, with its median value being $214934.5 (2022).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first tumbled by 9948.0% in 2021, then soared by 2618400.0% in 2022.
  • Quarter analysis of 5 years shows Seres Therapeutics' Gains from Sales and Divestitures stood at $650.0 in 2021, then soared by 43346.31% to $282401.0 in 2022, then soared by 439.89% to $1.5 million in 2023, then skyrocketed by 44.01% to $2.2 million in 2024, then plummeted by 97.62% to $52160.0 in 2025.
  • Its last three reported values are $52160.0 in Q3 2025, $35161.0 for Q2 2025, and $12966.0 during Q1 2025.